Immunopathological events in an experimental autoimmune kidney disease and how those events can be terminated to regain tolerance to self

Autoimmune Disorders: Symptoms, Diagnosis and Treatment

Volumn , Issue , 2011, Pages 35-66

  Barabas, Arpad Zsigmond ^a   Cole, Chad Douglas ^b   Weir, Donald Mackay ^c   Lafreniere, Rene ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Autoimmune diseases; Autoimmunity; Cancer; Modified vaccination technique

Indexed keywords

EID: 84867073317     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (143)

1. Alousi, MA; Post, RS; Heymann, W. Experimental autoimmune nephrosis in rats. Morphogenesis of the glomerular lesion: immunohistochemical and electron microscopic studies. Am. J. Pathol., 1969, 54, 47-71.
2. Andres, G; Brentjens, JR; Caldwell, PR; Camussi, G; Matsuo, S. Formation of immune deposits and disease. Lab Invest., 1986, 55, 510-20.
3. Aruffo, A; Hollenbaugh, D. Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease. Curr.Opin.Immunol., 2001, 13, 683-6.
4. Barabas, AZ; Cole, CD; Barabas, AD; Bahlis, NJ; Lafreniere, R. New vaccination technology for endogenous antigen-derived ailments. IDrugs., 2008, 11, 111-5.
5. Barabas, AZ; Cole, CD; Barabas, AD; Bahlis, NJ; Lafreniere, R. A vaccination technique to combat presently untreatable chronic ailments. Bio Processing Journal., 2007, 6, 12-8.
6. Barabas, AZ; Cole, CD; Barabas, AD; Barabas, AN; Lafreniere, R. Effect of rat kidney fraction 3 (rKF3) antigen and specific IgM antibody against rKF3 on the progression of slowly progressive Heymann nephritis. Pathol Int., 2006, 56, 516-29.
7. Barabas, AZ; Cole, CD; Barabas, AD; Barabas, AN; Lafreniere, R. Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev.Immunol., 2006, 13, 17-24.
8. Barabas, AZ; Cole, CD; Barabas, AD; Cowan, JM; Yoon, CS; Waisman, DM; et al. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int.J.Exp.Pathol., 2004, 85, 201-12.
9. Barabas, AZ; Cole, CD; Barabas, AD; Graeff, RM; Lafreniere, R; Weir, DM. Correcting autoimmune anomalies in autoimmune disorders by immunological means; employing the modified vaccination technique. Autoimmun Rev., 2009, 8, 552-7.
10. Barabas, AZ; Cole, CD; Barabas, AD; Graeff, RM; Lafreniere, R; Weir, DM. Application of the modified vaccination technique for the prevention and cure of chronic ailments. Asian Pacific Journal of Tropical Medicine., 2010, 3, 160-6.
11. Barabas, AZ; Cole, CD; Barabas, AD; Graeff, RM; Lafreniere, R; Weir, DM. Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders. Scandinavian Journal of Immunology., 2010, 71, 125-33.
12. Barabas, AZ; Cole, CD; Barabas, AD; Lafreniere, R. Production of a new model of slowly progressive Heymann nephritis. Int JExp Pathol., 2003, 84, 245-58.
13. Barabas, AZ; Cole, CD; Barabas, AD; Lafreniere, R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int. J. Exp. Pathol., 2004, 85, 321-34.
14. Barabas, AZ; Cole, CD; Barabas, AD; Lafreniere, R. Production of Heymann nephritis by a chemically modified renal antigen. Int. J. Exp. Pathol., 2004, 85, 277-85.
15. Barabas, AZ; Cole, CD; Barabas, AD; Lafreniere, R. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int., 2006, 56, 181-90.
16. Barabas, AZ; Cole, CD; Barabas, AD; Lafreniere, R. A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann. N.Y. Acad. Sci., 2007, 1110, 619-29.
17. Barabas, AZ; Cole, CD; Barabas, AD; Lafreniere, R. Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics: Targets & Therapy., 2007, 1, 59-68.
18. Barabas, AZ; Cole, CD; Barabas, AD; Lafreniere, R. An experimental autoimmune kidney disease caused by pathogenic autoantibodies. In Petrelli C; editor. New research on autoantibodies. Hauppauge NY: Nova Science Publishers; Inc.; 151-72.
19. Barabas, AZ; Cole, CD; Barabas, AD; Lafreniere, R. Pathogenic and nonpathogenic autoimmune events-the good and/or the bad? In Dubois Q; editor. Autoantibodies research progress. Hauppauge NY: Nova Science Publishers; Inc.; 9-18.
20. Barabas, AZ; Cole, CD; Kovacs, ZB; Lafreniere, R. Elevated antibody response by antigen presentation in immune complexes. Med Sci Monit., 2007, 13, BR119-BR124.
21. Barabas, AZ; Lafreniere, R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev., 2005, 4, 56570.
22. Barabas, AZ; Lannigan, R. Auto-immune nephritis in rats. J.Pathol., 1969, 97, 537-43.
23. Barabas, AZ; Lannigan, R; Jr. Induction of an autologous immune complex glomerulonephritis in the rat by intravenous injection of heterologous anti-rat kidney tubular antibody. II. Early glomerular lesions. Br.J.Exp.Pathol., 1974, 55, 282-90.
24. Barabas, AZ; Nagi, AH; Lannigan, R. Induction of Autologous Immune Complex Nephritis in Rats by Heterologous Anti-kidney Mitochondrial Antiserum. Int.Urol.Nephrol., 1970, 2, 303-8.
25. Barabas, AZ; Nagi, AH; Lannigan, R. Introduction of experimental glomerulonephritis by anti-kidney mitochondrial antiserum in the rabbit. Ulster Med J., 1971, 40, 67-71.
26. Barabas, AZ; Weir, DM; Cole, CD; Barabas, AD; Bahlis, NJ; Graeff, RM; et al. Preventing and treating chronic disorders using the modified vaccination technique. Front Biosci., 2009, 14, 3892-8.
27. Batsford, SR; Weghaupt, R; Takamiya, H; Vogt, A. Studies on the mesangial handling of protein antigens: influence of size; charge and biologic activity. Nephron., 1985, 41, 146-51.
28. Bitar, DM; Whitacre, CC. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell Immunol., 1988, 112, 364-70.
29. Blom, AM. Complement: deficiency diseases. Encyclopedia of life sciences. Chichester GB: John Wiley & Sons; Ltd.; 1-8.
30. Casali, P; Notkins, AL. CD5+ B lymphocytes; polyreactive antibodies and the human B-cell repertoire. Immunol.Today., 1989, 10, 364-8.
31. Challice, J; Barabas, AZ; Cornish, J; Bruce, JW; Lannigan, R. Passive Heymann nephritis in pre-and post-natal rats. Br.J.Exp.Pathol., 1986, 67, 915-24.
32. Chen, ZJ; Wheeler, J; Notkins, AL. Antigen-binding B cells and polyreactive antibodies. Eur.J.Immunol., 1995, 25, 579-86.
33. Conti, F; Rezai, S; Valesini, G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev., 2008, 8, 124-8.
34. Cornish, J; Barabas, AZ; Lannigan, R. Modified immunofluorescent antibody test: demonstration of nephritogenic antigen in glomeruli of rats. Diagn.Immunol., 1984, 2, 133-6.
35. Dass, S; Bowman, SJ; Vital, EM; Ikeda, K; Pease, CT; Hamburger, J; et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised; double-blind; placebo-controlled pilot study. Ann.Rheum.Dis., 2008, 67, 1541-4.
36. de Carvalho, JF; Pereira, RM; Shoenfeld, Y. The mosaic of autoimmunity: the role of environmental factors. Front Biosci.(Elite.Ed). 2009, 1, 501-9.
37. Dorner, T; Radbruch, A; Burmester, GR. B-cell-directed therapies for autoimmune disease. Nat.Rev Rheumatol., 2009, 5, 433-41.
38. Ebringer, A. Molecular mimicry as the basis of a new theory of autoimmunity. In Zouali M; editor. Frontiers in Autoimmunity: fundamental aspects and clinical perspectives. Amsterdam Netherlands: IOS Press; 79-99.
39. Ebringer, A; Rashid, T; Wilson, C. Rheumatoid arthritis: proposal for the use of antimicrobial therapy in early cases. Scand.JRheumatol., 2003, 32, 2-11.
40. Ebringer, A; Rashid, T; Wilson, C; Boden, R; Thompson, E. A possible link between multiple sclerosis and Creutzfeldt-Jakob disease based on clinical; genetic; pathological and immunological evidence involving Acinetobacter bacteria. Med Hypotheses., 2005, 64, 487-94.
41. Edgington, TS; Glassock, RJ; Dixon, FJ. Autologous immune-complex pathogenesis of experimental allergic glomerulonephritis. Science., 1967, 155, 1432-4.
42. Edgington, TS; Glassock, RJ; Dixon, FJ. Autologous immune complex nephritis induced with renal tubular antigen. I. Identification and isolation of the pathogenetic antigen. J.Exp.Med., 1968, 127, 555-72.
43. Edgington, TS; Glassock, RJ; Watson, JI; Dixon, FJ. Characterization and isolation of specific renal tubular epithelial antigens. J.Immunol., 1967, 99, 1199-210.
44. Edwards, JC; Cambridge, G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology.(Oxford)., 2001, 40, 20511.
45. Edwards, JC; Szczepanski, L; Szechinski, J; Filipowicz-Sosnowska, A; Emery, P; Close, DR; et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N.Engl.JMed., 2004, 350, 2572-81.
46. Ehrenfeld, EN; Gery, I; Davies, AM. Specific antibodies in heart disease. The Lancet., 1961, 1, 1138-41.
47. Feenstra, K; van den, LR; Greben, HA; Arends, A; Hoedemaeker, PJ. Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. I. The natural history: a histologic and immunohistologic study at the light microscopic and the ultrastructural level. Lab Invest., 1975, 32, 235-42.
48. Fleuren, GJ; vd, LR; Greben, HA; Van Damme, BJ; Hoedemaeker, PJ. Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. IV. Investigations into the pathogenesis of the model. Lab Invest., 1978, 38, 496-501.
49. Glassock, RJ; Edgington, TS; Watson, JI; Dixon, FJ. Autologous immune complex nephritis induced with renal tubular antigen. II. The pathogenetic mechanism. J.Exp.Med., 1968, 127, 573-88.
50. Grabar, P. Some considerations of the problem of auto-antibody formation. Tex.Rep.Biol.Med., 1965, 23, 278-84.
51. Grabar, P. Autoantibodies and the physiological role of immunoglobulins. Immunol.Today., 1983, 4, 337-40.
52. Guilherme, L; Fae, K; Oshiro, SE; Kalil, J. Molecular pathogenesis of rheumatic fever and rheumatic heart disease. Expert.Rev.Mol.Med., 2005, 7, 1-15.
53. Guilherme, L; Kalil, J; Cunningham, M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity., 2006, 39, 31-9.
54. Haddad, EE; Whitfill, CE; Avakian, AP; Ricks, CA; Andrews, PD; Thoma, JA; et al. Efficacy of a novel infectious bursal disease virus immune complex vaccine in broiler chickens. Avian Dis., 1997, 41, 882-9.
55. Hauser, SL; Waubant, E; Arnold, DL; Vollmer, T; Antel, J; Fox, RJ; et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N.Engl.J Med., 2008, 358, 676-88.
56. Hayashi, Y; Hironaka, K; Shikata, K; Ogawa, S; Ota, K; Wada, J; et al. Ultrastructure of glomerular basement membrane in active heymann nephritis rats revealed by tissue-negative staining method. Am.JNephrol., 2001, 21, 249-55.
57. Heymann, W; Grupe WE. Immunetolerance to experimental autoimmune nephrosis in rats. Proc.Soc.Exp.Biol.Med., 1970, 135, 184-7.
58. Heymann, W; Hackel, DB; Harwood, S; Wilson, SG; Hunter, JLP. Production of the nephritic syndrome in rat by Freund's adjuvant and rat kidney suspension. Proc.Soc.Exp.Biol.Med., 1959, 100, 660-4.
59. Heymann, W; Hunter, JLP; Hackel, DB. Experimental autoimmune nephrosis in rats. J.Immunol., 1962, 88, 135-41.
60. Heymann, W; Kmetec, EP; Wilson, SG; Hunter, JL; Hackel, DB; Okuda, R; et al. Experimental autoimmune renal disease in rats. Ann.N.Y.Acad Sci., 1965, 124, 310-22.
61. Heymann, W; Kmetec, EP; Wilson, SG; Hunter, JLP; Hackel DB; Cuppage, F. Experimental autoimmune renal disease in rats. In Grabar P; Miescher PA; (ed). IIIrd International Symposium of Immunopathology. Switzerland: Schwabe and Co.; Basel; 240-51.
62. Higgins, PJ; Weiner, HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol., 1988, 140, 440-5.
63. Hogan, SL; Muller, KE; Jennette, JC; Falk, RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am.J Kidney Dis., 1995, 25, 862-75.
64. Hu, C; Wong, FS; Wen, L. Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases. Clin Exp Immunol., 2009, 157, 181-90.
65. Jeurissen, SH; Janse, EM; Lehrbach, PR; Haddad, EE; Avakian, A; Whitfill, CE. The working mechanism of an immune complex vaccine that protects chickens against infectious bursal disease. Immunology., 1998, 95, 494-500.
66. Jung, S. Good; bad and beautiful--the role of dendritic cells in autoimmunity. Autoimmun.Rev., 2004, 3, 54-60.
67. Kamata, K; Baird, LG; Erikson, ME; Collins, AB; McCluskey, RT. Characterization of antigens and antibody specificities involved in Heymann nephritis. J.Immunol., 1985, 135, 2400-8.
68. Kanalas, J; Makker, SP. A 60kDa duplet polypeptide in normal rat serum and 60-68kDa polypeptides in gp 330-600 in kidney contain the cross reactive antigenic determinants against gp 330-600 autoantibody of Heymann nephritis (Abstract). Kidney Int., 1986, 29, 279.
69. Kerjaschki, D; Farquhar, MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc.Natl.Acad.Sci. U.S.A., 1982, 79, 5557-81.
70. Kerjaschki, D; Farquhar MG. Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J.Exp.Med., 1983, 157, 667-86.
71. Klaus, GG. The generation of memory cells. II. Generation of B memory cells with preformed antigen-antibody complexes. Immunology., 1978, 34, 643-52.
72. Kunkl, A; Klaus, GG. The generation of memory cells. IV. Immunization with antigen-antibody complexes accelerates the development of B-memory cells; the formation of germinal centres and the maturation of antibody affinity in the secondary response. Immunology., 1981, 43, 371-8.
73. Lafaille, JJ; Mathis, D. Immunological Yin-Yang. Curr Opin Immunol., 2002, 14, 7413.
74. Liu, Q; Kriksunov, IA; Graeff, R; Munshi, C; Lee, HC; Hao, Q. Crystal structure of human CD38 extracellular domain. Structure., 2005, 13, 1331-9.
75. Madaio, MP; Salant, DJ; Cohen, AJ; Adler, S; Couser, WG. Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. Kidney Int., 1983, 23, 498-505.
76. Makker, SP; Moorthy, B. In situ immune complex formation in isolated perfused kidney using homologous antibody. Lab Invest., 1981, 44, 1-5.
77. Manson, JJ; Mauri, C; Ehrenstein, MR. Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin.Immunopathol., 2005, 26, 425-32.
78. Manz, RA; Arce, S; Cassese, G; Hauser, AE; Hiepe, F; Radbruch, A. Humoral immunity and long-lived plasma cells. Curr Opin Immunol., 2002, 14, 517-21.
79. Mariette, X. Therapeutic potential for B-cell modulation in Sjogren's syndrome. Rheum.Dis.Clin North Am., 2008, 34, 1025-33, x.
80. Mendrick, DL; Noble, B; Brentjens, JR; Andres, GA. Antibody-mediated injury to proximal tubules in Heymann nephritis. Kidney Int., 1980, 18, 328-43.
81. Mevorach, D; Mascarenhas, JO; Gershov, D; Elkon, KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med., 1998, 188, 2313-20.
82. Miyakawa, Y; Kitamura, K; Shibata, S; Naruse. Demonstration of human nephritogenic tubular antigen in the serum and organs by radioimmunoassay. J.Immunol., 1976, 117, 1203-10.
83. Munshi, CB; Fryxell, KB; Lee, HC; Branton, WD. Large-scale production of human CD38 in yeast by fermentation. Methods Enzymol., 1997, 280, 318-30.
84. Nagler-Anderson, C; Bober, LA; Robinson, ME; Siskind, GW; Thorbecke, GJ. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci, U S A. 1986, 83, 7443-6.
85. Naruse, T; Fukasawa, T; Hirokawa, N; Oike, S; Miyakawa, Y. The pathogenesis of experimental membranous glomerulonephritis induced with homologous nephritogenic tubular antigen. J.Exp.Med., 1976, 144, 1347-62.
86. Naruse, T; Fukasawa, T; Miyakawa, Y. Laboratory model of membranous glomerulonephritis in rats induced by pronase-digested homologous renal tubular epithelial antigen. Lab.Invest., 1975, 33, 141-6.
87. Naruse, T; Fukasawa, T; Umegae, S; Oike, S; Miyakawa, Y. Experimental membranous glomerulonephritis in rats: correlation of ultrastructural changes with the serum level of autologous antibody against tubular antigen. Lab Invest., 1978, 39, 120-7.
88. Natori, Y; Hayakawa, I; Shibata, S. Passive Heymann nephritis with acute and severe proteinuria induced by heterologous antibody against renal tubular brush border glycoprotein gp108. Lab Invest., 1986, 55, 63-70.
89. Nawata, Y; Stall, AM; Herzenberg, LA; Eugui, EM; Allison, AC. Surface immunoglobulin ligands and cytokines differentially affect proliferation and antibody production by human CD5+ and CD5-B lymphocytes. Int Immunol., 1990, 2, 603-14.
90. Neale, TJ; Wilson, CB. Glomerular antigens in Heymann's nephritis: reactivity of eluted and circulating antibody. J Immunol., 1982, 128, 323-30.
91. Nie, X; Basu, S; Cerny, J. Immunization with immune complex alters the repertoire of antigen-reactive B cells in the germinal centers. Eur J Immunol., 1997, 27, 3517-25.
92. Noble, B; Van Liew, JB; Brentjens, JR; Andres, GA. Effect of reimmunization with Fx1A late in the course of Heymann nephritis. Lab Invest., 1982, 47, 427-36.
93. Orbach, H; Shoenfeld, Y. Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel; Lausanne; Switzerland. Autoimmun Rev., 2007, 6, 261-6.
94. Pavkova, L. Formation and significance of autoantibodies in burned patients. Vox Sang., 1962, 7, 116.
95. Peakman, M; Dayan, CM. Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire? Immunology., 2001, 104, 361-6.
96. Perkinson, DT; Baker, PJ; Couser, WG; Johnson, RJ; Adler, S. Membrane attack complex deposition in experimental glomerular injury. Am.J.Pathol., 1985, 120, 121-8.
97. Perna, A; Schieppati, A; Zamora, J; Giuliano, GA; Braun, N; Remuzzi, G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am. J. Kidney Dis., 2004, 44, 385-401.
98. Perosa, F; Favoino, E; Caragnano, MA; Prete, M; Dammacco, F. CD20, a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev., 2005, 4, 526-31.
99. Quartier, P; Potter, PK; Ehrenstein, MR; Walport, MJ; Botto, M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur.JImmunol., 2005, 35, 252-60.
100. Quigg, RJ; Cybulsky, AV; Jacobs, JB; Salant, DJ. Anti-Fx1A produces complement-dependent cytotoxicity of glomerular epithelial cells. Kidney Int., 1988, 34, 43-52.
101. Radbruch, A; Muehlinghaus, G; Luger, EO; Inamine, A; Smith, KG; Dorner, T; et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev Immunol., 2006, 6, 741-50.
102. Rammensee, HG; Weinschenk, T; Gouttefangeas, C; Stevanovic, S. Towards patient-specific tumor antigen selection for vaccination. Immunol Rev., 2002, 188, 164-76.
103. Raychowdhury, R; Zheng, G; Brown, D; McCluskey, RT. Induction of Heymann nephritis with a gp330/megalin fusion protein. Am.J.Pathol., 1996, 148, 1613-23.
104. Rich, MW. Drug-induced lupus. The list of culprits grows. Postgrad.Med., 1996, 100, 299-8.
105. Ronco, P; Allegri, L; Brianti, E; Chatelet, F; Van Leer, EH; Verroust, P. Antigenic targets in epimembranous glomerulonephritis. Experimental data and potential application in human pathology. Appl.Pathol., 1989, 7, 85-98.
106. Ronco, P; Debiec, H. Molecular dissection of target antigens and nephritogenic antibodies in membranous nephropathy: towards epitope-driven therapies. J.Am.Soc.Nephrol., 2006, 17, 1772-4.
107. Rosenmann, E; Dishon, T; Boss, JH. Ultrastructural alterations of the glomeruli after prolonged immunization. Correlation with urinary excretion of kidney specific antigens in the rat. Beitr.Pathol., 1973, 149, 227-40.
108. Rosenmann, E; Dishon, T; Durst, A; Boss, JH. Urinary excretion of kidney antigens in experimental renal diseases of the rat. Br.J.Exp.Pathol., 1971, 52, 388-94.
109. Salant, DJ; Cybulsky, AV. Experimental glomerulonephritis. Methods Enzymol., 1988, 162, 421-61.
110. Salant, DJ; Quigg, RJ; Cybulsky, AV. Heymann nephritis: mechanisms of renal injury. Kidney Int., 1989, 35, 976-84.
111. Schulze, C; Munoz, LE; Franz, S; Sarter, K; Chaurio, RA; Gaipl, US; et al. Clearance deficiency--a potential link between infections and autoimmunity. Autoimmun Rev., 2008, 8, 5-8.
112. Selmi, C; Battezzati, PM; Gershwin, ME; Tishler, M; Shoenfeld, Y. Vaccines in the 21st century: the genetic response and the innocent bystander. Autoimmun Rev., 2005, 4, 79-81.
113. Shirai, T. The genetic basis of autoimmunity in murine lupus. Immunol.Today., 1982, 3, 187-94.
114. Singh, AK; Kasinath, BS. Metabolic fate of monovalent and multivalent antibodies of Heymann nephritis following formation of surface immune complexes on glomerular epithelial cells. Clin.Exp.Immunol., 1993, 94, 403-11.
115. Singh, AK; Makker, SP. Circulatory antigens of Heymann nephritis. I. Identification and partial characterization. Immunology., 1986, 57, 467-72.
116. Singh, AK; Schwartz, MM. Circulatory antigen of Heymann nephritis. II. Isolation of a 70, 000 MW antigen from normal rat serum which cross-reacts with Heymann nephritis antigen. Immunology., 1986, 59, 451-8.
117. Stenglein, B; Thoenes, GH; Gunther, E. Genetically controlled autologous immune complex glomerulonephritis in rats. J Immunol., 1975, 115, 895-7.
118. Stenglein, B; Thoenes, GH; Gunther, E. Genetic control of susceptibility to autologous immune complex glomerulonephritis in inbred rat strains. Clin.Exp.Immunol., 1978, 33, 88-94.
119. Stoner, RD; Terres, G. Enhanced antitoxin responses in irradiated mice elicited by complexes of tetanus toxoid and specific antibody. J Immunol., 1963, 91, 761-70.
120. Stoner, RD; Terres, G; Hess, MW. Early and enhanced antioxin responses elicited with complexes of tetanus toxoid and specific mouse and human antibodies. J Infect.Dis., 1975, 131, 230-8.
121. Terres, G; Morrison, SL; Habicht, GS; Stoner, RD. Appearance of an early "primed state" in mice following the concomitant injections of antigen and specific antiserum. J Immunol., 1972, 108, 1473-81.
122. Terres, G; Stoner, RD. Specificity of enhanced immunological sensitization of mice following injections of antigens and specific antisera. Proc Soc.Exp Biol.Med., 1962, 109, 88-91.
123. Terres, G; Wolins, W. Enhanced sensitization in mice by simultaneous injection of antigen and specific rabbit antiserum. Proc Soc.Exp Biol.Med., 1959, 102, 632-5.
124. Terres, G; Wolins, W. Enhanced immunological sensitization of mice by the simultaneous injection of antigen and specific antiserum. I. Effect of varying the amount of antigen used relative to the antiserum. J Immunol., 1961, 86, 361-8.
125. Theofilopoulos, AN. The basis of autoimmunity: Part II. Genetic predisposition. Immunol.Today., 1995, 16, 150-9.
126. Thompson, HSG; Staines, NA. Gastric administration of type II collagen delays the onset and severity of collegen induced arthritis in rats. Clin Exp Immunol., 1985, 64, 581-6.
127. Trentham, DE; Dynesius-Trentham, RA; Orav, EJ; Combitchi, D; Lorenzo, C; Sewell, KL; et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science, 1993, 261, 1727-30.
128. Tsukada, Y; Ono, K; Maezawa, A; Yano, S; Naruse, T. A major pathogenic antigen of Heymann nephritis is present exclusively in the renal proximal tubule brush border--studies with a monoclonal antibody against pronase-digested tubular antigen. Clin.Exp.Immunol., 1994, 96, 303-10.
129. Van Damme, BJ; Fleuren, GJ; Bakker, WW; Vernier, RL; Hoedemaeker, PJ. Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest., 1978, 38, 502-10.
130. Watson, JI; Dixon, FJ. Experimental glomerulonephritis. IX. factors influencing the development of kidney in adjuvant nephritis in rats. Proc.Soc.Exp.Biol.Med., 1966, 121, 216-23.
131. Weiner, HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today., 1997, 18, 335-43.
132. Weiner, HL; Mackin, GA; Matsui, M; Orav, EJ; Khoury, SJ; Dawson, DM; et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science., 1993, 259, 1321-4.
133. Weir, DM. Immunological reaction after tissue injury. Lancet., 1964, 1, 749-50.
134. Weir, DM. The immune response after tissue injury. Pathol.Eur., 1966, 1, 108-18.
135. Weir, DM. The immunologicial consequences of cell death. Lancet., 1967, 2, 1071-3.
136. Weir, DM. Altered antigens and autoimmunity. Vox Sang., 1969, 16, 304-13.
137. Weir, DM; Elson, CJ. Antitissue antibodies and immunological tolerance to self. Arthritis Rheum., 1969, 12, 254-60.
138. Weir, DM; Pinckard, RN. Failure to induce tolerance to rat tissue antigens. Immunology., 1967, 13, 373-80.
139. Weir, DM; Pinckard, RN; Elson, CJ; Suckling, DE. Naturally occurring anti-tissue antibodies in rat sera. Clin.Exp.Immunol., 1966, 1, 433-42.
140. Wermeling, F; Karlsson, MC; McGaha, TL. An anatomical view on macrophages in tolerance. Autoimmun Rev., 2009, 9, 49-52.
141. Whitfill, CE; Haddad, EE; Ricks, CA; Skeeles, JK; Newberry, LA; Beasley, JN; et al. Determination of optimum formulation of a novel infectious bursal disease virus (IBDV) vaccine constructed by mixing bursal disease antibody with IBDV. Avian Dis., 1995, 39, 687-99.
142. Wucherpfennig, KW. Structural basis of molecular mimicry. J.Autoimmun., 2001, 16, 293-302.
143. Yung, R; Powers, D; Johnson, K; Amento, E; Carr, D; Laing, T; et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J.Clin.Invest., 1996, 97, 2866-71.